SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Regulatory Order SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Inclusion of Sun Pharma in the S&P Global Sustainability Yearbook 2024
Buy Sun Pharma; target of Rs 1635: Motilal Oswal
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1635 in its research report dated January 31, 2024. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding Loss of Share Certificate
Sun Pharma Advanced Research Com Q3 FY24 results: loss at 99.65Cr, Revenue decreased by 89.43% YoY
Sun Pharma Advanced Research Com Q3 FY24 results: Revenue decreased by 89.43% YoY & loss at 99.65Cr SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Incorporation Of A Subsidiary Company
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation of a Subsidiary Company SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
SPIL Q3FY24 Earnings Call Transcript SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Incorporation Of A Subsidiary Company
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 - Incorporation of a Subsidiary Company SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Sun Pharma Q3 Results Review - Specialty Scale Up To Drive Growth: Yes Securities
Sun Pharma reported a steady set of numbers with revenue and Ebidta growth of 10% and 11.5% YoY respectively.